Artemisinin potentiates apoptosis and triggers cell cycle arrest to attenuate malignant growth of salivary gland tumor cells

Peng Xiao¹, Qiujuan Liang², Qiuqiu Chen³ and Haixia Liu⁴✉

¹Department of Stomatology, The Seventh Affiliated Hospital of Xinjiang Medical University, Urumqi 830028, Xinjiang, China; ²Department of Stomatology, The Fifth Affiliated Hospital of Xinjiang Medical University, Urumqi 830000, Xinjiang, China; ³Department of Stomatology, The Second Affiliated Hospital of Zhejiang University of Chinese Medicine, Hangzhou 310005, Zhejiang, China; ⁴Department of Stomatology, Yangpu District Central Hospital of Shanghai (Yangpu Hospital Affiliated From Tongji University), Shanghai 200090, China

One of the rare malignant tumors developing within the glands of the buccal cavity in human beings is salivary gland tumors (SGTs). The hallmark of SGTs is the fusion of nuclear factor IB (NFIB) and myeloblastosis (MYB) genes developed after the translocation of q22-23; p23-24. Although the aetiology of SGTs is not clear, however, the therapeutic modalities are surgical resection followed by the combination of chemotherapy and radiotherapy if a chance of recurrence seems to develop. Owing to have numerous side effects of chemotherapy, the drug development has been shifted to natural products with minimal side effects. One of the key phytochemical artemisinin derived from wormwood Artemisia annua exhibits various pharmacological activities against various in-vivo and in-vitro cellular models. Here, we evaluated the cytotoxic potential of artemisinin against A-253 cells with possible underlying cell death mechanisms. Our results showed that artemisinin reduces the proliferation of cells in a concentration-dependent manner and displays IC₅₀ value in a range of 10.23, 14.21 μM, and 203.18 μM against A-253/HTB-41 and transformed salivary gland SMIE cells, respectively. Flow cytometry analysis demonstrated that artemisinin promotes a significant amount of apoptotic cellular population and triggers G₁/G₀ arrest of A-253 cells in a concentration-dependent manner. To verify the mechanism of cell death induced by artemisinin in A-253 cells, we found an increased level of Bax, Bim, Bad, Bak and reduced level of antiapoptotic protein Bcl-2, Bcl-xl with concomitant release of mitochondrial resident protein cytochrome c into the cytoplasm. Additionally, we found that artemisinin augments the production of reactive oxygen species which further leads to the activation of proapoptotic proteins PARP1, and caspase-3, in a concentration-dependent manner thereby triggering apoptosis. In conclusion, artemisinin exhibits promising anticancer therapeutic potential against A-253 cells and needs further validation of in-vitro results in preclinical models.

Keywords: Artemisinin, apoptosis, salivary gland tumors, cell death, chemotherapy

Received: 31 August, 2021; revised: 21 October, 2021; accepted: 02 December, 2021; available on-line: 13 February, 2022

✉e-mail: yzx5051hx@sina.com

Acknowledgements of Financial Support: The current study was funded by an intramural grant from the Central Hospital of Shanghai.

Abbreviations: SGTs, Salivary gland tumors; NFIB, nuclear factor IB; MYB, myeloblastosis; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; DMEM, Dulbecco’s modified Eagle’s medium; FBS, fetal bovine serum; PI, propidium iodide; PMSF, phenylmethylsulfonyl fluoride; DTT, dithiothreitol; DMSO, dimethyl sulfoxide; HRP, horseradish peroxidase; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis; PVD, polyvinylidene fluoride; PBS, phosphate buffered saline; TBST, tris-buffered saline tween-20; PI3K/Akt, phosphoinositide 3-kinase/protein kinase B; Mcl-1, myeloid leukemia; Bcl-2, B-cell lymphoma; Bcl-xl, B-cell lymphoma extra large; Bim, B-cell-like protein 11; Bak, Bcl-2 homologous antagonist/killer; Bax, Bcl-2 associated x protein; ANT, adenine nucleotide translocator; VDAC, voltage-dependent anion channel; JC-1, 5,5,6,6’-tetrachloro-1,1’,3,3’-tetrathylbenzimidazolocarbocyanine iodide (JC-1); H₂O₂, hydrogen peroxide; DCFHDA, 7’-dichlorofluorescein diacetate (DCFHDA); DAPI, 4,6-diamidino-2-phenylindole; NAC, N-acetylcysteine; MMP, mitochondrial membrane potential

INTRODUCTION

Salivary gland tumors (SGTs) are a rare group of complex with heterogeneous histology that is developed from the parotid, sublingual, and submandibular glands of the buccal cavity (Namboodiripad, 2014). The striking feature of human SGTs is the translocation of q22-23, p23-24, a fusion of nuclear factor IB (NFIB), and myeloblastosis (MYB) proto-oncogenes located on chromosome 9p and 6q, respectively (Škalová et al., 2018). This fusion promotes the development of heterogeneity and resistance to available conventional therapies and often makes SGT’s diagnosis, therapeutics, and prognosis worst (Wysoki et al., 2016). The treatments of choice in SGTs are the complete removal of primary lesions of glands affected with malignancies. The advanced rate of progression of metastatic SGTs often has a dismal prognosis with a survival period that ranges from 6 to 9 months (Adams et al., 2013). The recent reports suggest that the development of therapeutic resistance to SGTs was due to the upregulation of phosphoinositide 3-kinase/protein kinase B (PI3K/Akt) signaling pathway (Adams et al., 2015). This aberration of the PI3K/Akt pathway promotes the upregulation of downstream mediators of antiapoptotic proteins (myeloid leukemia-Mcl-1, B-cell lymphoma-Bcl-2, and B-cell lymphoma extra large-Bcl-xl) and downregulation of proapoptotic proteins (B-cell-like protein 11-Bim, Bel-2 homologous antagonist/killer-Bak, and Bel-2 associated x protein-Bax) and supports the notion that high Bel-2/Bax ratio could lead to poor prognosis in the salivary gland tumors (Xie et al., 1999, Patterson et al., 2005). Recent data revealed that silencing of Bcl-2 or blocking Bcl-2 homology domain-3 (BH3) – a domain of proapoptotic proteins by mimetics in A-253 cells could be the ideal choice to deal with poor prognosis of salivary gland malignancies (Pattinage et al., 2005).
The key hallmark of malignant cells is the development of resistance to programmed cell death. Therefore, augmentation of programmed cell death and attenuation of cellular growth by triggering cell cycle arrest is the primary aim of almost all anticancer therapeutics to kill malignant cells without eliciting inflammation (Viktorsson et al., 2005). One of the key cellular organelles, the mitochondria, is critically important in dealing with intrinsic apoptosis and targeting mitochondria in malignant cells is the ideal choice for anticancer therapeutics (Leibowitz & Yu, 2010). The striking feature of mitochondrial-dependent apoptosis is depolarisation of inner mitochondrial membrane potential with the concomitant discharge of mitochondrial resident and proapoptotic protein cytochrome c into the cytosol (Wu & Bratton, 2013). These events lead to the activation of caspase-9 which triggers the initiation of caspase activation thereby leading to condensation of DNA and eventually cell death. Additionally, loss of mitochondrial membrane potential (MMP) induces the formation of pores in an inner mitochondrial membrane by oligomerization of Bak/Bax monomers to release cytochrome c for the execution of apoptosis (Wu & Bratton, 2013). However, the antiapoptotic proteins function in reverse by interacting with proapoptotic proteins Bax/Bak to inhibit the oligomerization of Bax/Bak thereby preventing the execution of apoptosis (Wu & Bratton, 2013).

Intracellular reactive oxygen species (ROS) are mainly produced by the mitochondrial electron transport chain (ETC) and play a dual role in promoting carcinogenesis signaling cascade or inducing cell death. An abrupt rise in intracellular ROS often culminates in the induction of pro-death signals in the tumor cells (Thangam et al., 2014). ROS regulate mitochondrial resident proteins such as adenine nucleotide translocator (ANT), voltage-dependent anion channel (VDAC), and associated components of oxidative phosphorylation to promote loss of MMP or may modulate redox enzyme functions, thereby attenuating cellular antioxidant mechanisms to favour programmed cell death (Zorov et al., 2014). In contrast, tumor cells of various malignancies either have a low level of antioxidant activity or are deficient in one or more enzymes compared to normal cells to neutralize the reactive oxygen species (Yamamoto et al., 2003). Owing to having low antioxidant capacities or defective antioxidant enzymatic machinery in many malignant cells due to ROS (Ryter et al., 2007; Antosiewicz et al., 2008), we hypothesize that induction of ROS-mediated cell death in salivary gland tumor cells could be the ideal strategy to develop novel chemotherapeutics in SGTs.

In the recent past, natural compounds from plant sources received great attention in drug discovery programs against various types of cancers. Artemisinin a principle compound derived from Artemisia annua has been used long back in China as traditional medicine against various ailments such as antimalarial, anti-inflammation, immunomodulation, and antibacterial activity (Swargiary et al., 2020). Owing to having numerous medicinal properties, artemisinin exhibits promising antiproliferative and cell death-inducing potential in a wide variety of human cancer cell models both in vitro and in vivo settings (Jamalzadeh et al., 2017). Mechanistically, artemisinin attenuates tumor progression by induction of apoptosis, autophagy, and promotes antiangiogenic effect by inhibition of angiogenesis (Wong et al., 2017). Besides inhibition of PI3K/Akt signaling and nuclear factor kappa B (NF-κB) downregulation, artemisinin has been reported to promote ROS induction in cellular models (Wong et al., 2017). However, abrupt stimulation of ROS, activation of pro-apoptotic activity, and cell cycle arrest by artemisinin in A-253 cells are unexplored.

Therefore, the current evaluation was aimed to investigate the antiproliferative, apoptotic-inducing, and cell cycle arrest by artemisinin against SGTCs (A-253/HTB-41). Our results showed that artemisinin brings on the promising antiproliferative potential against A-253 cells. Mechanistically, we observe the loss of MMP, activation of apoptosis signaling with concomitant downregulation, and upregulation of Bel-2/Bel-x and Bad/Bax/Bak/Bim, respectively in A-253 cells exposed to the dose-dependent treatment of artemisinin. Subsequently, we found dose-dependent cell cycle arrest at G1/G0 phase in A-253 cells. Additionally, we found abrupt induction of ROS generation in salivary gland tumor cells exposed to artemisinin which could further augment the mitochondrial-dependent apoptosis mechanism of artemisinin against A-253 cells.

**MATERIAL AND METHODS**

**Cell culture, reagents, and treatments**

Salivary gland tumor cell line (A-253/HTB-41) and normal transformed submandibular epithelial SMIE rat cells were procured from American Type Culture Collection (ATCC). The cell lines were cultured under aseptic conditions in respective McCoy’s 5a, and Dulbecco’s modified Eagle’s (DMEM) culture medium obtained from Invitrogen. The cultured media were supplemented with L-glutamine, 10% fetal bovine serum, and 1% penicillin-streptomycin from Invitrogen. The cell lines were cultured under aseptic conditions in respective McCoy’s 5a, and Dulbecco’s modified Eagle’s (DMEM) culture medium obtained from Invitrogen. The cultured media were supplemented with L-glutamine, 10% fetal bovine serum, and 1% penicillin-streptomycin from Invitrogen to inhibit any bacterial growth. All the cells were timely checked for mycoplasma contamination. The artemisinin was obtained from Sigma-Aldrich and was dissolved in dimethyl sulfoxide (DMSO) to make a 20 mM stock solution for experimentation. The artemisinin treatments to A-253 cells were dose-dependent (10, 20, and 30 μM) for 24 h.

**Chemicals and antibodies**

Propidium iodide (PI), artemisinin, 5,5,6,6′-tetracloro-1,1′,3,3′-tetrathyldienbenzimidiazolocarbocyanine iodide (JC-1), hydrogen peroxide (H2O2), 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT), staurosporine, dimethyl sulphoxide (DMSO), 7′-dichlorofluorescein diacetate (DCFHDA), 4′,6-diamidino-2-phenylindole (DAPI), and N-acetylcyesteine (NAC) were obtained from the Sigma-Aldrich. The required polyclonal primary antibodies (Bel-2, Bax, Bim, Bak, cytochrome c, β-actin, PARP1, Bel-xL, Bel-2, VDAC, and caspase-3) were purchased from the Cell Signaling Technology. The HRP-conjugated rabbit and mouse IgG secondary antibodies were from Sigma-Aldrich.

**Cell viability assay**

The cell viability of A-253 cells was evaluated by the commonly used MTT assay (Rah et al., 2012). Briefly, 5×104 A-253 cells were seeded in each well of the 96-well plate and incubated for more than 8 hr to adhere properly to the plate surface. A-253 cells were treated with varying doses of artemisinin (10, 20, and 30 μM) for 24 h. After treatment, cells were exposed to 20 μL (2.5 mg/mL) of MTT dye for 3-4 h. After the completion of incubation, 150 μL of DMSO was added to dissolve formazan crystals. The color solution obtained after gentle shaking was measured at 570 nm by using a multivariate reader. The absorbance was recorded, and
cell viability was determined as cell viability in an artesiminin-treated group to that of cell viability in the untreated control group.

Quantification of an apoptotic population of cells

The apoptotic cell population was quantified by flow cytometry as determined previously. (Alnuqaydan et al., 2020). Briefly, 5×10^3 A-253 cells were treated with artemisinin in a dose-dependent manner (10, 20, and 30 μM) in a 6-well plate for 24 h at 37°C. After incubation, cells were harvested from each well, washed thrice with pre-cooled PBS, and then resuspended in a binding buffer provided in the apoptosis detection kit (Sigma-Aldrich). The cells were then incubated with fluorescein isothiocyanate (FITC)-conjugated annexin V antibody (5 μL) and PI (5 μL) in dark at 4°C for 15 min. Incubated samples containing suspended cells were operated and evaluated for quantification of apoptosis by flow cytometry (BD Bioscience).

Cell cycle analysis

Different stages of the cell cycle of A-253 cells after exposure to various doses of artemisinin (10, 20, and 30 μM) were analyzed by using flow cytometry (Alnuqaydan and Rah 2021). Briefly, 0.5×10^5 A-253 cells were plated and exposed to various doses of artemisinin (10, 15, and 20 μM), camptothecin (1 μM) as a positive control, and DMSO as untreated control. After 24 h treatment, cells were harvested, washed with pre-cooled phosphate-buffered saline (PBS), and then fixed at −20°C with 70% ethanol overnight. After fixation, cells were subjected to RNAs (100 μg/mL) treatment for 30 min at 37°C, followed by staining with propidium iodide (50 μg/mL) for another 30 min at 4°C. Using the BDTM LSR II flow cytometry system, processed A-253 cells were analyzed and quantified in various phases of the cell cycle.

Collection of cytosolic and mitochondrial fractions from A-253 for western blotting

Cytosolic and mitochondrial fractions were collected as described previously (Rah et al., 2015a). After 24 h treatment of A-253 cells with artemisinin in a dose-dependent manner (10, 15 and 20 μM), along with DMSO as untreated control, cells were scrapped/trypsinized, harvested, and washed with ice-cooled PBS. The washed cells were incubated and resuspended in buffer A (1 mM dithiothreitol (DTT), 200 mM sucrose, 1mg/mL bovine serum albumin (BSA), 1 mM ethylene glycol-bis (β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid (EGTA) and 10 mM pH 7.4 Tris-MOPS) and were lysed by passing through 18-gauge syringe needle many times. The cell lysates in buffer A obtained were centrifuged (0.1 h, 1000g) at 4–8°C. The supernatants were again centrifuged (15 min, 15000×g) at 4°C to separate mitochondria. The supernatants obtained after second centrifugation contained only cytosolic protein fraction and the pellet obtained contained mitochondrial fraction. The respective fractions thus obtained were subjected to Bradford analysis to measure protein concentration. After calculating the concentration of protein, 20–30 μg of protein from both the fractions of all treatments were loaded in sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gel to resolve proteins based on molecular weight under the standard voltage 100 V. Resolved proteins were transferred on to the PVDF membrane, followed by incubation of transferred polyvinylidene fluoride (PVDF) membrane with 5% skimmed milk as blocking solution in TBST to avoid any non-specific antibody binding. Incubation of PVDF membrane with primary antibody was performed either for 3–4 h at room temperature or for overnight at 4 °C on the shaker to ensure uniform binding of an antibody to the corresponding antigen. After incubation of PVDF membrane containing transferred proteins with antibodies solution (dilution 1:1000), PVDF membrane was washed with TBST for 5 min (3 times) and incubated with corresponding secondary antibodies (horseradish peroxidase-HRP-conjugated, dilution 1:10000) at 37°C for 1 to 1.5 h. PVDF membranes were washed again with TBST for 5 min (3 times), cleaned, and incubated with ECL reagent to detect the presence of protein on the PVDF membrane by capturing fluorescence on the X-ray film or with chemiluminescence based gel doc.

Reactive oxygen species detection and estimation by Dichloro-dihydro-fluorescein diacetate (DCFHDA) method

The detection and estimation of ROS were evaluated by the DCFH-DA method (Eruslanov and Kusmartsev 2010). Briefly, 10^4 A-253 cells in a 6-well plate were exposed with the artemisinin in a concentration-dependent manner (10, 15, and 20 μM) in the presence or absence of N-acetylcysteine (NAC) (5 mM) and a positive control H_2O_2 and DMSO as untreated control for 24 h at 37°C. After 24 h treatment, A-253 cells were washed with ice-cooled PBS followed by incubation with DCFH-DA dye for half an hour at 37°C. After 30 min photographs of stained cells were captured with a fluorescent microscope and subsequently cell plates were analyzed by recording fluorescence at excitation wavelength 488 nm and emission wavelength 525 nm.

Evaluation of depolarization of mitochondrial membrane potential (MMP)

The mitochondrial membrane potential of A-253 cells was analyzed by JC-1 staining (Clayton & Shadel, 2014; Rah et al., 2015a). After seeding cells at a density of 5×10^3 in each well of 6-well plate, A-253 cells were exposed to dose-dependent treatment with artemisinin (10, 15, and 20 μM) and staurosporine as positive control and DMSO as untreated control at 37°C. After 24 h incubation, cells were harvested, washed with pre-cooled PBS. The collected cells were processed for JC-1 staining at room temperature for 20 min. The cells which have intact mitochondria exhibit bright red fluorescence whereas those cells which are in a process or undergo apoptosis have depolarization of MMP exhibited green fluorescence. The change in fluorescence (red/green) was used to determine the healthy versus depolarization MMP. The stained cell suspension was analyzed to quantify the MMP of the cell population exposed to various treatments of artemisinin by flow cytometry (BD Bioscience).

Phase-contrast microscopy

A-253 cells were seeded at a density of 0.5×10^6 cells in each well of a sterile 6-well plate. Cells were incubated for overnight to get properly adhered to at 37°C in a 5% CO_2 incubator. Next, A-253 cells were exposed to various doses of artemisinin (10, 15, and 20 μM), staurosporine (25 nM) as a positive control, and DMSO as untreated control for 24 h at 37°C. After completion of time point, A-253 cells were directly
analyzed by phase-contrast microscope (Nikon Eclipse TS100) by capturing photographs and analyzing the morphological changes induced by artemisinin.

**Statistical analysis**

The experimental data from the above experimental assays were performed more than three times and the data represent the mean ± standard error of the mean (S.E.M.). The data from all experiments were calculated by using one-way ANOVA analysis. The \( p \)-value ≤ 0.05 is taken as significant.

**RESULTS**

Artemisinin reduces the proliferation of human A-253 cells in a concentration-dependent manner

To evaluate the influence of artemisinin on cell viability, all the cell lines (A-253/HTB-41 and SMIE) seeded in 96-well sterile plates were exposed to varying doses of artemisinin (0.1–100 μM) for 24 h. We observed a dose-dependent reduction in cell viability in all the cell lines used in the MTT assay. When calculating the IC\(_{50}\) dose after 24 h exposure to artemisinin, we found 10.23±0.25 μM for A-253 and 14.21±0.38 μM for HTB-41 cells (Fig. 1A). Intriguingly, we found quite a high IC\(_{50}\) value (203.18±3.24 μM) against normal transformed human salivary gland SMIE cells (Fig. 1B). These results indicate that artemisinin specifically and significantly reduces the cell viability of human A-253 cells in comparison with normal SMIE cells.

Further, to support the reduction of cell viability by artemisinin, we perform phase-contrast microscopy to determine the morphological changes after artemisinin treatment. Upon dose-dependent exposure to artemisinin (10, 15, and 20 μM) treatment and staurosporine (25 nM) as a positive control, and DMSO as untreated control at 37°C for 24 h, cells were harvested and processed to determine the apoptotic cell population by flow cytometry. Our results revealed a dose-dependent induction of apoptosis caused by artemisinin in A-253 cells. The results showed that a substantial amount of population of apoptotic cells was induced (12.87±1.03%, 17.86±1.35%, and 24.74±1.97%) at varying doses of artemisinin (10, 15, and 20 μM), respectively, compared to untreated control 5.82±0.07% in A-253 cells. Additionally, a significant induction of apoptosis (39.8±3.3%) was also observed in A-253 cells after

![Figure 1. Evaluation of cell viability of cultured salivary gland tumor cells (A-253 cells).](image)

**Artemisinin promotes dose-dependent apoptosis and triggers G\(_0\)/G\(_1\) cell cycle arrest in human A-253 cells**

Next, we tried to evaluate the underlying cell death mechanism induced by artemisinin in human A-253 cells. After exposure to artemisinin (10, 15, and 20 μM) or staurosporine (25 nM) as a positive control, and DMSO as untreated control at 37°C for 24 h, cells were harvested and processed to determine the apoptotic cell population by flow cytometry. Our results revealed a dose-dependent induction of apoptosis caused by artemisinin in A-253 cells. The results showed that a substantial amount of population of apoptotic cells was induced (12.87±1.03%, 17.86±1.35%, and 24.74±1.97%) at varying doses of artemisinin (10, 15, and 20 μM), respectively, compared to untreated control 5.82±0.07% in A-253 cells. Additionally, a significant induction of apoptosis (39.8±3.3%) was also observed in A-253 cells after

![Figure 2. Morphological changes in A-253 cells after treatment with artemisinin.](image)
24 h treatment with staurosporine (25 nM) as a positive control (Fig. 3A and B).

Further, induction of apoptosis by dose-dependent treatment of cells with artemisinin was analyzed by western blotting to determine the protein level of activated apoptotic proteins. After dose-dependent treatment of A-253 cells with artemisinin (10, 15 and 20 μM) and staurosporine (25 nM) as a positive control, and DMSO as untreated control, for 24 h at 37°C cell lysates from different treatments of artemisinin were analyzed by western blotting to evaluate the relative protein level of apoptotic proteins. Immunoblotting findings demonstrated that at higher doses of artemisinin, A-253 cells showed the activation of proapoptotic Poly [ADP-ribose] polymerase 1 (PARP1) and caspase-3 protein forms into respective active products (Fig. 3C).

Additionally, we also used flow cytometry analysis to investigate the influence of artemisinin on the cell cycle of A-253 cells. After exposure to artemisinin (10, 15, and 20 μM) and camptothecin (1 μM) as positive control and DMSO as an untreated control at 37°C for 24 h, A-253 cells were harvested and processed to determine the different phases of the cell cycle by flow cytometry. Our results of flow cytometry analysis revealed a dose-dependent arrest of the G0/G1 phase of the cell cycle (54.57±1.03%, 63.17±1.35%, and 74.27±1.97%) at varying doses of artemisinin (10, 15 and 20 μM), respectively compared to positive control camptothecin (1 μM) and untreated control (Fig. 4A and 4B). Together these results suggest that artemisinin induces an antiproliferative effect in human A-253 cells by inducing apoptotic mechanism of cell death as well as G0/G1 cell cycle arrest in A-253 cells.

Induction of apoptosis by artemisinin in A-253 cells is mitochondrial-dependent

To evaluate the role of mitochondria in artemisinin-induced apoptosis, we determined mitochondrial mem-
brane potential in artemisinin-treated A-253 cells. The A-253 cells were exposed to various doses of artemisinin (10, 15, and 20 μM) and staurosporine (25 nM) as a positive control, DMSO as untreated control for 24 h. The A-253 cells were processed and stained with JC-1 dye to evaluate ψMMP by flow cytometry analysis. Our findings demonstrate a significant loss of ψMMP (76.72±0.83%, 84.32±1.21%, and 93.14±1.71%) corresponding to 10, 15 and 20 μM artemisinin concentrations respectively, compared to DMSO control cells (09.14±0.71%). The A-253 cells treated with 25 nM staurosporine (positive control) presented a significant loss of ψMMP (96.74±3.31%) (Fig. 5A and B).

The loss of ψMMP promotes disruption of the inner mitochondrial membrane causing the release of mitochondrial resident protein cytochrome c into the cytoplasm (Madungwe et al., 2018). To check whether cytochrome c is released after depolarization of mitochondrial membrane potential of A-253 cells by varying doses of artemisinin we performed subcellular fractionation followed by immunoblotting of both cytosolic and mitochondrial fractions. Our immunoblotting results demonstrated that the level of cytochrome c in cytosolic fraction increases as the doses of artemisinin increase and concomitantly the level of cytochrome c in mitochondrial fractionation decreases as the treatment dose of artemisinin increases. Intriguingly, we observed an increased level of proapoptotic proteins Bax, Bim, Bad, and Bak in mitochondrial fraction than in a cytosolic fraction (Fig. 5C). These data indicate that loss of ψMMP induced by artemisinin was augmented by Bax, Bim, Bad, and Bak to form pores in the outer mitochondrial membrane thereby allowing free movement to the mitochondrial resident protein cytochrome c to form apoptosome and execute mitochondrial-dependent apoptosis in A-253 cells.

Induction of ROS by artemisinin augments mitochondrial-dependent apoptosis in A-253 cells

Induction of ROS such as hydrogen peroxide (H2O2) and O₂•− implicates both cell survival as well as cell death depending upon the level of induction. Artemisinin has been reported to induce ROS production in various cellular models (Chong & Zheng, 2016). Therefore, we determined the ROS production by artemisinin treatment in A-253 cells and whether the artemisinin-mediated ROS production in A-253 cells helps in cell survival or favours cell death. After dose-dependent treatment of A-253 cells with artemisinin (10, 15 and 20 μM) along with the presence of ROS inhibitor NAC (5 mM) (Halasi et al., 2013), ROS inducer hydrogen peroxide (H2O2) (100 μM) as a positive control (Wu et al., 2018), and DMSO as untreated control for 24 h. The cells were processed for DCFH-DA staining to measure the intracellular ROS production by oxidizing and converting DCFH-DA dye to green fluorescent DCF probe and the intensity of green fluorescent is directly proportional to oxidative stress induced by ROS (Nayak & Mishra, 2020). Recent reports suggest that various natural compounds promote antiproliferative effects by inducing ROS production in various cancer cell models (NavaneethaKrishnan et al., 2019, Şoica et al., 2020). Consistent with previous studies, our results showed that artemisinin abruptly induces ROS production, and the level of ROS production increases as the dose of artemisinin increases. We found a 1.7 to

Figure 4. Evaluation of cell cycle analysis by flow cytometry of A-253 cells with dose-dependent artemisinin treatment.
(A) Analysis of various cell cycle stages by flow cytometry after treatment with varying doses of artemisinin (10, 15, 20 μM) along with positive control camptothecin 1 μM and DMSO (less than 1%) as untreated control to quantify the cells in different stages of the cell cycle in A-253 cells. (B) The bar chart represents the percentage of G0/G1 triggered cell cycle arrest with the indicated doses (10, 15, 20 μM) of artemisinin and positive control camptothecin 1 μM after treatment of A-253 cells for 24 h at 37ºC. All the experiments were performed in triplicates (n=3), each error bar designates standard error of three independent experiments and are statistically significant (p≤0.5).
9.3-fold increase in ROS level in the dose-dependent treatment of A-253 cells exposed to artemisinin when compared to untreated control. H$_2$O$_2$ exposed cells presented 7-times higher ROS levels than untreated control cells. Additionally, cells exposed to a higher dose of artemisinin (20 μM) followed by treatment with NAC have a 1.1-fold higher intracellular ROS level than untreated control (Fig. 6A and B). Further, the report suggests that ROS production by natural compound with aferin A facilitates mitochondrial-dependent cell killing in colorectal cancer cells (Xia et al., 2018). Additionally, prenylated isoflavone auriculasin derived from F. philippinensis promotes ROS induction in prostate cancer cells thereby activating apop-
Consistent with these reports, we observed that artemisinin induces ROS production in A-253 cells thereby promoting apoptosis. Further, our immunoblotting results revealed that activation of proapoptotic proteins PARP-1 and caspase-3 were observed with a concomitant reduction in the protein level of antiapoptotic Bcl-2 and Bcl-xL after A-253 cells at higher doses of artemisinin for 24 h (Fig. 6C). Intriguingly, pre-treatment of cells with a higher dose of artemisinin (20 μM) followed by N-acetylcysteine treatment, does not activate PARP-1, and caspase-3 proapoptotic proteins with the negligible decrease in antiapoptotic proteins Bcl-xL and Bcl-2 were observed (Fig. 6C). These data suggest that artemisinin promotes abrupt ROS production which further augments the artemisinin-induced apoptosis in A-253 cells.

**DISCUSSION**

One of the key mechanisms to prevent tumorigenesis is the execution of apoptosis to malignant cells (Rah et al., 2016). Most chemotherapeutic drugs in response to death signals generated within the cells by DNA damage or oncogenic activation promote apoptosis induction (Nayak et al., 2015; Rah et al., 2015b). Numerous chemotherapeutic drugs activate mitochondrial membrane-dependent apoptosis and often crosstalk with extrinsic apoptosis pathways to promote an effective mode of cell death to tumor cells (Sharma et al., 2012; Sinha et al., 2013; ur Rasool et al., 2016). In response to apoptotic stimuli, the striking feature of the internal (mitochondrial-dependent) apoptotic pathway is the release of mitochondrial resident proteins into the cytoplasm (Ahnqaydan et al., 2020) such as cytochrome c which pro-
motes initiation of apoptosome formation thereby activating other proapoptotic proteins such as caspase-3, -9, etc to activate apoptosis (Mignotte & Vayssiere, 1998). Previous reports suggested that numerous natural compounds could induce cell death mechanisms in tumor cells by activating mitochondrial-dependent apoptosis. Rigo and Vinante (Rigo & Vinante, 2016) demonstrated that z-Bisabolol promotes intrinsic apoptosis cell death in tumor cells both in a concentration-dependent as well as time-dependent manner. Further, the study reveals that induction of cell death was due to loss of ψMMP. Consistent with these studies our results demonstrated that dose-dependent exposure of A-253 cells to artemisinin promotes significant loss of mitochondrial membrane potential. This was evidenced by the release of cytochrome c and other prominent mitochondrial resident proteins such as Bim, Bad, Bak, and Bax into the cytosolic fraction (Fig. 5C and 5D).

Anticancer drugs kill tumor malignant cells mainly by apoptosis as well as trigger cell cycle arrest to attenuate the tumor cell growth (Zilla et al., 2014; Dar et al., 2018; Alnuqaydan et al., 2020). Luo and others (Luo et al., 2018) showed that 6-Gingerol promotes apoptosis and subsequently triggers cell cycle arrest of gastric carcinoma cells to reduce the growth of malignant cells (Luo et al., 2018). Another similar study suggests that artemisinin interrupts transcriptional factor E2F thereby triggering G1 phase cell cycle arrest in breast cancer (MCF-7) cells (Tin et al., 2012). Consistent with previous results, our cell cycle analysis demonstrates that artemisinin induces G1/G0 phase cell cycle arrest in A-253 cells in a dose-dependent manner.

Generation of intracellular ROS by dose-dependent treatment of artemisinin seems upstream incident of the mitochondrial-dependent apoptosis in A-253 cells. This is evidenced by the significantly reduced apoptotic population of A-253 cells that are pre-treated with artemisinin followed by NAC (5 mM) treatment for 24 h. Previous reports suggest that artemisinin induces apoptosis in various cellular models through different cell death cascade mechanisms (Gao et al., 2011). However, our results suggest that induction of ROS generation by artemisinin in A-253 cells could be an early event, and as the treatment time proceeds the generation of ROS could further augment the artemisinin-induced apoptosis in A-253 cells. The explanation for the high induction of apoptosis by artemisinin could be due to low or defect in one or more enzymes that promote antioxidant activity in A-253 cells. Artemisinin a natural phytomedicinal compound that possesses prooxidant activity further weakens the antioxidant system of salivary gland tumor cellular models thereby inducing ROS generation that promotes cell death mechanism in A-253 cells.

An antiapoptotic mechanism is mainly contributed by elevated Bcl-xL and Bcl-2 levels in cells and thus contributes to chemoresistance (Choudhary et al., 2015). Whether these antiapoptotic proteins could have any role in SGT metastasis is not yet clear. To investigate whether the expression of key antiapoptotic proteins Bcl-xL, Bak and Bax are elevated in A-253/HTB-41 cells to drive them towards the development of drug resistance. We intended to correlate the level of antiapoptotic and apoptotic proteins of untreated and artemisinin-treated A-253 cells in the current study. We found a substantial decrease in the protein level of antiapoptotic Bcl-xL and Bcl-2 with concomitant upregulation and activation of proapoptotic proteins PARP-1, and caspase-3 in A-253 cells exposed with dose-dependent treatment with artemisinin. Additionally, studies revealed that a combination of chemotherapeutic drugs could sensitize malignant cells to cell death often frequently by modulating the relative ratio of various proapoptotic and antiapoptotic Bcl-2 families of proteins (Tagscherer et al., 2008). Upregulation of Bcl-2 and Bcl-XL antiapoptotic protein prevents the apoptotic activity of proapoptotic Bim, Bad, Bak, and Bak proteins by influencing the ratio of proapoptotic to antiapoptotic proteins (Kang & Reynolds, 2009). Further, the ectopic level of Bel-2 in leukemia cells prevents apoptosis significantly by modulating the proapoptotic and antiapoptotic protein level by artemisinin (Kim et al., 2013; Kumar et al., 2017). Consistent with earlier results (Ho et al., 2014; Wang et al., 2019), we found that artemisinin treatment of A-253 cells for 24 h modulates the proapoptotic to antiapoptotic protein ratio in favour of apoptosis activation by upregulating and downregulating the protein level of Bim, Bad, Bak and Bel-2 and Bcl-xL, respectively.

In conclusion, our results demonstrate that artemisinin exhibits a promising antiproliferative effect against A-253 cells at low micromolar doses. Mechanistically, artemisinin promotes ROS-mediated mitochondrial-dependent apoptotic cell death and triggers G1/G0 cell cycle arrest. This was evidenced by loss of ψMMP, the liberation of cytochrome c from the inner membrane of mitochondria, caspase cascade activation, and downregulation of antiapoptotic Bel-xL and Bel-2. Owing to having either low antioxidant activity or having a defective antioxidant system in malignant cells compared to normal cells, the artemisinin could be used in combination with other prooxidants drugs against salivary gland tumors to promote ROS-mediated cell death specifically in salivary gland tumor cellular models.

Acknowledgments

The author’s thanks to the Department of Stomatology, Yangpu District Central Hospital of Shanghai for their technical support.

Authors contributions

Peng Xiao performs conceptualization, data curation, visualization, and formal analysis. Qiujuan Liang helps in manuscript writing, conceptualization, and review editing. Qiaqi Chen performs and designs experiments, Huxia Liu conceptualization, writing, editing, and making an original draft of the manuscript.

Conflict of Interest

The authors declare no conflict of interest

REFERENCES

Antosiewicz J, Zdokkowski W, Kar S, Powolny AA, Singh SV (2008) Role of reactive oxygen intermediates in cellular responses to di-


